Horizon Therapeutics [HZNP] vs Merck & Co [MRK] Detailed Stock Comparison

Horizon Therapeutics Plc

NASDAQ
Loading...

Merck & Co., Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Horizon Therapeutics Plc wins in 4 metrics, Merck & Co., Inc. wins in 13 metrics, with 0 ties. Merck & Co., Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Horizon Therapeutics Plc Merck & Co., Inc. Better
P/E Ratio (TTM) 61.86 15.74 Merck & Co., Inc.
Price-to-Book Ratio 5.01 5.39 Horizon Therapeutics Plc
Debt-to-Equity Ratio 0.48 95.96 Horizon Therapeutics Plc
PEG Ratio -16.29 -0.82 Merck & Co., Inc.
EV/EBITDA 24.08 10.97 Merck & Co., Inc.
Profit Margin (TTM) 74.64% 28.08% Horizon Therapeutics Plc
Operating Margin (TTM) 16.83% 32.77% Merck & Co., Inc.
EBITDA Margin (TTM) 16.83% 32.77% Merck & Co., Inc.
Return on Equity 10.28% 36.88% Merck & Co., Inc.
Return on Assets (TTM) 5.72% 12.04% Merck & Co., Inc.
Free Cash Flow (TTM) N/A $12.36B N/A
Dividend Yield N/A 2.91% N/A
1-Year Return -6.82% 45.70% Merck & Co., Inc.
Price-to-Sales Ratio (TTM) 7.34 4.35 Merck & Co., Inc.
Enterprise Value $26.84B $319.41B Merck & Co., Inc.
EV/Revenue Ratio 7.40 4.91 Merck & Co., Inc.
Gross Profit Margin (TTM) 76.72% 66.15% Horizon Therapeutics Plc
Revenue per Share (TTM) $16 $26 Merck & Co., Inc.
Earnings per Share (Diluted) $2.22 $7.28 Merck & Co., Inc.
Beta (Stock Volatility) N/A 0.28 N/A
Short % of Float N/A 1.12% N/A

Horizon Therapeutics Plc vs Merck & Co., Inc. Stock Performance Analysis

Loading Price Chart...

HZNP
MRK

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Horizon Therapeutics Plc0.00%N/AN/AN/AN/AN/A
Merck & Co., Inc.-3.49%-3.87%3.16%-0.46%14.60%7.94%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Horizon Therapeutics Plc-6.82%74.04%9.84%176.66%176.66%176.66%
Merck & Co., Inc.45.70%8.90%55.40%123.23%252.74%262.85%

Performance & Financial Health Analysis: Horizon Therapeutics Plc vs Merck & Co., Inc.

MetricHZNPMRK
Market Information
Market Cap i$26.63B$283.10B
Market Cap CategoryLarge capMega cap
10 Day Avg. Volume i19,134,2069,732,998
90 Day Avg. Volume i8,460,6959,710,049
Last Close$116.30$114.90
52 Week Range$116.30 - $116.34$76.66 - $125.14
% from 52W High-0.03%-8.18%
All-Time High$39.49 (Jul 20, 2015)$134.63 (Jun 24, 2024)
% from All-Time High194.50%-14.65%
Growth Metrics
Quarterly Revenue Growth0.14%0.05%
Quarterly Earnings GrowthN/A-0.21%
Financial Health
Profit Margin (TTM) i0.75%0.28%
Operating Margin (TTM) i0.17%0.33%
Return on Equity (TTM) i0.10%0.37%
Debt to Equity (MRQ) i0.4895.96
Cash & Liquidity
Book Value per Share (MRQ)$23.22$21.26
Cash per Share (MRQ)N/A$5.89
Operating Cash Flow (TTM) i$1.33B$16.47B
Levered Free Cash Flow (TTM) i$1.81B$11.89B
Dividends
Last 12-Month Dividend Yield iN/A2.91%
Last 12-Month Dividend iN/A$3.32

Valuation & Enterprise Metrics Analysis: Horizon Therapeutics Plc vs Merck & Co., Inc.

MetricHZNP (Apr 30, 2025)MRK (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i61.8615.74
Forward P/E i20.5511.80
PEG Ratio i-16.29-0.82
Price to Sales (TTM) i7.344.35
Price to Book (MRQ) i5.015.39
Market Capitalization
Market Capitalization i$26.63B$283.10B
Enterprise Value i$26.84B$319.41B
Enterprise Value Metrics
Enterprise to Revenue i7.404.91
Enterprise to EBITDA i24.0810.97
Risk & Other Metrics
Beta iN/A0.28
Book Value per Share (MRQ) i$23.22$21.26

Financial Statements Comparison: Horizon Therapeutics Plc vs Merck & Co., Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricHZNPMRK (2025)
Revenue/Sales iN/A65.01B
Cost of Goods Sold iN/A16.38B
COGS % of Revenue i-25.2%
Gross Profit iN/A48.63B
Gross Margin i-74.8%
Research & Development iN/A15.79B
Operating Income (EBIT) iN/A22.11B
Operating Margin i-34.0%
EBITDA iN/A29.11B
EBITDA Margin i-44.8%
Pre-Tax Income iN/A21.07B
Pre-Tax Income % of Revenue i-32.4%
Income Tax iN/A2.80B
Income Tax % of Revenue i-4.3%
Net Income (Profit) iN/A18.26B
Profit Margin i-28.1%

Balance Sheet & Liquidity Metrics

MetricHZNPMRK (2025)
Cash & Equivalents iN/A14.57B
Total Current Assets iN/A43.52B
Total Current Assets % of Revenue i-66.9%
Total Current Liabilities iN/A28.33B
Total Current Liabilities % of Revenue i-43.6%
Long-Term Debt iN/A46.75B
Long-Term Debt % of Revenue i-71.9%
Total Shareholders Equity iN/A52.66B
Retained Earnings iN/A73.08B
Retained Earnings % of Revenue i-112.4%
Property, Plant & Equipment iN/A0

Cash Flow Statement Comparison

MetricHZNPMRK (2025)
Operating Cash Flow iN/A18.49B
Operating Cash Flow % of Revenue i-28.4%
Capital Expenditures iN/AN/A
Free Cash Flow iN/A12.36B
FCF Margin i-19.0%
Debt Repayment iN/A-2.50B
Common Stock Repurchase iN/A-5.08B

Short Interest & Institutional Ownership Analysis

MetricHZNPMRK
Shares Short iN/A27.72M
Short Ratio iN/A2.69
Short % of Float iN/A1.12%
Shares Outstanding i229.00M2.47B
Float Shares iN/A2.47B
% Held by Insiders iN/A0.06%
% Held by Institutions iN/A81.44%
% Held by Public iN/A18.50%

Dividend Analysis & Yield Comparison: Horizon Therapeutics Plc vs Merck & Co., Inc.

MetricHZNPMRK
Last 12-Month Dividend iN/A$3.32
Last 12-Month Dividend Yield iN/A2.91%
3-Year Avg Annual Dividend iN/A$3.16
3-Year Avg Dividend Yield iN/A0.77%
3-Year Total Dividends iN/A$9.48
Ex-Dividend DateN/AMar 16, 2026